drugset / Trial / NCT04920448
N-ACETYLCYSTEINE FOR THROMBOLYSIS IN ACUTE STROKE
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to assess the safety of N-Acetylcysteine as a thrombolytic agent in acute ischemic stroke, especially regarding the risk of hemorrhagic transformation.
Timeline
- Start
- 2021-06-16
- Primary completion
- 2023-04-25
- Completion
- 2024-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 150 mg/kg | Intravenous |